These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1074 related articles for article (PubMed ID: 33737337)

  • 21. State of the art in immunotherapy of neuroblastoma.
    Jabbari P; Hanaei S; Rezaei N
    Immunotherapy; 2019 Jun; 11(9):831-850. PubMed ID: 31094257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.
    Esser R; Müller T; Stefes D; Kloess S; Seidel D; Gillies SD; Aperlo-Iffland C; Huston JS; Uherek C; Schönfeld K; Tonn T; Huebener N; Lode HN; Koehl U; Wels WS
    J Cell Mol Med; 2012 Mar; 16(3):569-81. PubMed ID: 21595822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Lin28 axis enhances glypican-3-CAR T cell efficacy against hepatic tumor initiating cell population.
    Patra T; Cunningham DM; Meyer K; Toth K; Ray RB; Heczey A; Ray R
    Mol Ther; 2023 Mar; 31(3):715-728. PubMed ID: 36609146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining Immunocytokine and
    Bates PD; Rakhmilevich AL; Cho MM; Bouchlaka MN; Rao SL; Hales JM; Orentas RJ; Fry TJ; Gilles SD; Sondel PM; Capitini CM
    Front Immunol; 2021; 12():668307. PubMed ID: 34489927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.
    Ciccone R; Quintarelli C; Camera A; Pezzella M; Caruso S; Manni S; Ottaviani A; Guercio M; Del Bufalo F; Quadraccia MC; Orlando D; Di Cecca S; Sinibaldi M; Aurigemma M; Iaffaldano L; Sarcinelli A; D'Amore ML; Ceccarelli M; Nazio F; Marabitti V; Giorda E; Pezzullo M; De Stefanis C; Carai A; Rossi S; Alaggio R; Del Baldo G; Becilli M; Mastronuzzi A; De Angelis B; Locatelli F
    Clin Cancer Res; 2024 Jun; 30(11):2545-2557. PubMed ID: 38551501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.
    Heczey A; Liu D; Tian G; Courtney AN; Wei J; Marinova E; Gao X; Guo L; Yvon E; Hicks J; Liu H; Dotti G; Metelitsa LS
    Blood; 2014 Oct; 124(18):2824-33. PubMed ID: 25049283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TIM-3/Gal-9 interaction induces IFNγ-dependent IDO1 expression in acute myeloid leukemia blast cells.
    Folgiero V; Cifaldi L; Li Pira G; Goffredo BM; Vinti L; Locatelli F
    J Hematol Oncol; 2015 Apr; 8():36. PubMed ID: 25886742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAR T Cell Therapy for Neuroblastoma.
    Richards RM; Sotillo E; Majzner RG
    Front Immunol; 2018; 9():2380. PubMed ID: 30459759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.
    Huang Q; Xia J; Wang L; Wang X; Ma X; Deng Q; Lu Y; Kumar M; Zhou Z; Li L; Zeng Z; Young KH; Yi Q; Zhang M; Li Y
    J Hematol Oncol; 2018 Apr; 11(1):58. PubMed ID: 29685162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
    Long AH; Highfill SL; Cui Y; Smith JP; Walker AJ; Ramakrishna S; El-Etriby R; Galli S; Tsokos MG; Orentas RJ; Mackall CL
    Cancer Immunol Res; 2016 Oct; 4(10):869-880. PubMed ID: 27549124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.
    Andersch L; Radke J; Klaus A; Schwiebert S; Winkler A; Schumann E; Grunewald L; Zirngibl F; Flemmig C; Jensen MC; Rossig C; Joussen A; Henssen A; Eggert A; Schulte JH; Künkele A
    BMC Cancer; 2019 Sep; 19(1):895. PubMed ID: 31500597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.
    Bocca P; Di Carlo E; Caruana I; Emionite L; Cilli M; De Angelis B; Quintarelli C; Pezzolo A; Raffaghello L; Morandi F; Locatelli F; Pistoia V; Prigione I
    Oncoimmunology; 2017; 7(1):e1378843. PubMed ID: 29296542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patients' NK cell stimulation with activated plasmacytoid dendritic cells increases dinutuximab-induced neuroblastoma killing.
    Belounis A; Ayoub M; Cordeiro P; Lemieux W; Teira P; Haddad E; Herblot S; Duval M
    Cancer Immunol Immunother; 2020 Sep; 69(9):1767-1779. PubMed ID: 32342128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.
    Tarek N; Le Luduec JB; Gallagher MM; Zheng J; Venstrom JM; Chamberlain E; Modak S; Heller G; Dupont B; Cheung NK; Hsu KC
    J Clin Invest; 2012 Sep; 122(9):3260-70. PubMed ID: 22863621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells.
    Mitwasi N; Feldmann A; Arndt C; Koristka S; Berndt N; Jureczek J; Loureiro LR; Bergmann R; Máthé D; Hegedüs N; Kovács T; Zhang C; Oberoi P; Jäger E; Seliger B; Rössig C; Temme A; Eitler J; Tonn T; Schmitz M; Hassel JC; Jäger D; Wels WS; Bachmann M
    Sci Rep; 2020 Feb; 10(1):2141. PubMed ID: 32034289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization.
    Grunewald L; Lam T; Andersch L; Klaus A; Schwiebert S; Winkler A; Gauert A; Heeren-Hagemann AI; Astrahantseff K; Klironomos F; Thomas A; Deubzer HE; Henssen AG; Eggert A; Schulte JH; Anders K; Kloke L; Künkele A
    Front Immunol; 2021; 12():689697. PubMed ID: 34267756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
    Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk
    Wei JS; Kuznetsov IB; Zhang S; Song YK; Asgharzadeh S; Sindiri S; Wen X; Patidar R; Najaraj S; Walton A; Auvil JMG; Gerhard DS; Yuksel A; Catchpoole D; Hewitt SM; Sondel PM; Seeger R; Maris JM; Khan J
    Clin Cancer Res; 2018 Nov; 24(22):5673-5684. PubMed ID: 29784674
    [No Abstract]   [Full Text] [Related]  

  • 40. Identification of hub genes and their correlation with infiltration of immune cells in
    Chen J; Sun M; Chen C; Jiang B; Fang Y
    Front Immunol; 2022; 13():1016683. PubMed ID: 36311753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.